Evidence map›Paper›PMID 37243081›Full record

ArticleVaccines2023

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV.

Hiva Azizi, Jason P Knapp, Yue Li, Alice Berger, Marc-Alexandre Lafrance, Jannie Pedersen, Marc-Antoine de la Vega, Trina Racine, Chil-Yong Kang, Jamie F S Mann and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Hiva AziziDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
Jason P KnappDepartment of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.ORCID 0000-0003-2147-6000
Yue LiDepartment of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.
Alice BergerDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
Marc-Alexandre LafranceDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0002-6680-5691
Jannie PedersenDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
Marc-Antoine de la VegaDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
Trina RacineDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0001-6370-8661
Chil-Yong KangDepartment of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.
Jamie F S MannBristol Veterinary School, University of Bristol, Langford House, Langford, BS40 5DU Bristol, UK.
Jimmy D DikeakosDepartment of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.
Gary KobingerGalveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Eric J ArtsDepartment of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.
Western University · CAUniversité Laval · CANational Research Council Canada · CAThe University of Texas Medical Branch at Galveston · USUniversity of Bristol · GBUniversity of Saskatchewan · CA

Funding

Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
HIV-1 Fitness and RecombinationR56AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2012 to 2012
$400k
Impact of HIV-1 Fitness on Disease ProgressionR21AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2001 to 2001
$265k
CIHR 421693NIAID NIH HHS R01 AI049170NIAID NIH HHS R21 AI049170NIAID NIH HHS R56 AI049170NIH HHS AI49170
6 · The paper itself

Abstract

Vesicular stomatitis virus (VSV) remains an attractive platform for a potential HIV-1 vaccine but hurdles remain, such as selection of a highly immunogenic HIV-1 Envelope (Env) with a maximal surface expression on recombinant rVSV particles. An HIV-1 Env chimera with the transmembrane domain (TM) and cytoplasmic tail (CT) of SIVMac239 results in high expression on the approved Ebola vaccine, rVSV-ZEBOV, also harboring the Ebola Virus (EBOV) glycoprotein (GP). Codon-optimized (CO) Env chimeras derived from a subtype A primary isolate (A74) are capable of entering a CD4+/CCR5+ cell line, inhibited by HIV-1 neutralizing antibodies PGT121, VRC01, and the drug, Maraviroc. The immunization of mice with the rVSV-ZEBOV carrying the CO A74 Env chimeras results in anti-Env antibody levels as well as neutralizing antibodies 200-fold higher than with the NL4-3 Env-based construct. The novel, functional, and immunogenic chimeras of CO A74 Env with the SIV_Env-TMCT within the rVSV-ZEBOV vaccine are now being tested in non-human primates.

Indexed as

Ebola virus glycoproteinHIV-1 Envelope glycoproteinhuman immunodeficiency virus type 1 (HIV-1)vesicular stomatitis virus (VSV) vector

Identifiers

PMID37243081
PMCPMC10223473
OpenAlexW4376274404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.